207 related articles for article (PubMed ID: 32536947)
21. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database.
Park S; Kim Y; Lee GH; Choi SA
Sci Rep; 2023 Oct; 13(1):17607. PubMed ID: 37848636
[TBL] [Abstract][Full Text] [Related]
22. Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma.
Dedaj R; Unsel L
J Asthma; 2019 May; 56(5):473-474. PubMed ID: 29733738
[TBL] [Abstract][Full Text] [Related]
23. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
[TBL] [Abstract][Full Text] [Related]
24. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
Scioscia G; Tondo P; Nolasco S; Pelaia C; Carpagnano GE; Caiaffa MF; Valenti G; Maglio A; Papia F; Triggiani M; Crimi N; Pelaia G; Vatrella A; Foschino Barbaro MP; Crimi C
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445397
[TBL] [Abstract][Full Text] [Related]
25. Real-world effectiveness of dupilumab versus benralizumab and mepolizumab.
Bleecker E; Blaiss M; Jacob-Nara J; Huynh L; Guo T; Ye M; Stanford RH; Wang Z; Soler X; Nag A; Nair R; Borsos K
Allergy Asthma Proc; 2024 May; ():. PubMed ID: 38760161
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Akenroye A; Lassiter G; Jackson JW; Keet C; Segal J; Alexander GC; Hong H
J Allergy Clin Immunol; 2022 Nov; 150(5):1097-1105.e12. PubMed ID: 35772597
[TBL] [Abstract][Full Text] [Related]
27. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
[TBL] [Abstract][Full Text] [Related]
28. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
29. A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM).
Menzella F; Fontana M; Galeone C; D'Amato M; Canonica GW; Ghidoni G; Capobelli S; Scelfo C; Simonazzi A; Catellani C; Ruggiero P; Facciolongo N
J Asthma Allergy; 2021; 14():1019-1031. PubMed ID: 34413654
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Nopsopon T; Lassiter G; Chen ML; Alexander GC; Keet C; Hong H; Akenroye A
J Allergy Clin Immunol; 2023 Mar; 151(3):747-755. PubMed ID: 36538979
[TBL] [Abstract][Full Text] [Related]
31. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
32. Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use.
Kimura Y; Suzukawa M; Inoue N; Imai S; Akazawa M; Matsui H
World Allergy Organ J; 2021 Nov; 14(11):100600. PubMed ID: 34820049
[TBL] [Abstract][Full Text] [Related]
33. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
Sabbe M; Schleich F; Janssens P; Louis R
J Med Case Rep; 2024 Jan; 18(1):63. PubMed ID: 38291489
[TBL] [Abstract][Full Text] [Related]
34. Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty.
Menzella F; Galeone C; Lusuardi M; Simonazzi A; Castagnetti C; Ruggiero P; Facciolongo N
Ther Clin Risk Manag; 2017; 13():1489-1493. PubMed ID: 29184413
[TBL] [Abstract][Full Text] [Related]
35. Clinical effects and immune modulation of biologics in asthma.
Harada N; Ito J; Takahashi K
Respir Investig; 2021 Jul; 59(4):389-396. PubMed ID: 33893067
[TBL] [Abstract][Full Text] [Related]
36. Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial.
Sánchez J; García E; Lopez JF; Calle A; Buendia JA
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2172-2179. PubMed ID: 37146885
[TBL] [Abstract][Full Text] [Related]
37. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.
Jackson K; Bahna SL
Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421
[No Abstract] [Full Text] [Related]
38. COVID-19 in a patient with severe asthma using mepolizumab.
Aksu K; Yesilkaya S; Topel M; Turkyilmaz S; Ercelebi DC; Oncul A; Kalkan IK; Ates H
Allergy Asthma Proc; 2021 Mar; 42(2):e55-e57. PubMed ID: 33536114
[No Abstract] [Full Text] [Related]
39. Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.
Cameli P; Aliani M; Altieri E; Bracciale P; Brussino L; Caiaffa MF; Canonica GW; Caruso C; Centanni S; D'Amato M; De Michele F; Del Giacco S; Di Marco F; Pelaia G; Rogliani P; Romagnoli M; Schino P; Schroeder JW; Senna G; Vultaggio A; Benci M; Boarino S; Menzella F
J Asthma Allergy; 2024; 17():273-290. PubMed ID: 38562251
[TBL] [Abstract][Full Text] [Related]
40. Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases.
Pitlick MM; Pongdee T
World Allergy Organ J; 2022 Nov; 15(11):100707. PubMed ID: 36267353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
